ArticleScientific reports2026
The influence of menopausal phase on atrial fibrillation risk in steatotic liver disease patients: a nationwide cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Atrial fibrillation (AF) risk is influenced by sex hormones and steatotic liver disease (SLD), but their interplay in women remains unclear. We aimed to evaluate the impact of various SLD statuses on AF risk among premenopausal and postmenopausal women. Total 2,181,691 women from the 2009 Korean National Health Insurance Service screenings were analyzed, excluding those with prior AF, hysterectomy, liver cancer, or transplantation. Participants were classified by menopausal status and SLD type: No SLD, metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD with combined etiologies, MASLD and increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD). Over 8.3 years of follow-up, postmenopausal women (n = 903,079) were older with higher body mass index and comorbidities, while premenopausal women (n = 1,278,613) more often smoked and consumed alcohol. In premenopausal women, AF incidence ranged from 0.65 per 1,000 person-years without SLD to 1.67 in ALD, with the highest hazard ratio in ALD (HR 2.16, 95% CI 1.27-3.67). Postmenopausal women showed higher absolute AF incidence (3.43-5.44) but attenuated hazard ratios, peaking at 1.66 in ALD. SLD is significantly associated with increased AF risk, peaking in premenopausal women with MASLD or ALD; these findings necessitate early cardiovascular risk assessment and AF screening, warranting further research into preventive strategies. These novel findings establish a significant association between SLD and increased AF risk across all menopausal stages, demonstrating that the highest relative risk is disproportionately concentrated in premenopausal women with MASLD or ALD, thus underscoring the urgent need for enhanced cardiovascular surveillance and status-specific primary prevention strategies in this overlooked younger population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.